AnaptysBio Financial Statements From 2010 to 2024

ANAB Stock  USD 22.27  1.10  5.20%   
AnaptysBio financial statements provide useful quarterly and yearly information to potential AnaptysBio investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on AnaptysBio financial statements helps investors assess AnaptysBio's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting AnaptysBio's valuation are summarized below:
Gross Profit
-78.5 M
Profit Margin
(2.90)
Market Capitalization
644.2 M
Enterprise Value Revenue
4.0326
Revenue
57.2 M
We have found one hundred twenty available fundamental signals for AnaptysBio, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of AnaptysBio prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road.

AnaptysBio Total Revenue

24.42 Million

Check AnaptysBio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AnaptysBio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2 M, Interest Expense of 19 M or Selling General Administrative of 44 M, as well as many indicators such as Price To Sales Ratio of 31.93, Dividend Yield of 0.0 or PTB Ratio of 6.22. AnaptysBio financial statements analysis is a perfect complement when working with AnaptysBio Valuation or Volatility modules.
  
Check out the analysis of AnaptysBio Correlation against competitors.
For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.

AnaptysBio Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets354.3 M452.4 M260.6 M
Slightly volatile
Short and Long Term Debt Total10.8 M17.8 M8.1 M
Slightly volatile
Other Current Liabilities30.6 M29.2 M7.6 M
Slightly volatile
Total Current Liabilities19.3 M37.4 M14.8 M
Slightly volatile
Total Stockholder Equity83.7 M88.1 M164.9 M
Slightly volatile
Property Plant And Equipment Net19.2 M18.3 MM
Slightly volatile
Current Deferred Revenue6.5 M11.7 M6.3 M
Slightly volatile
Accounts Payable4.2 M4.7 M3.1 M
Slightly volatile
Cash34.2 M36 M92.7 M
Slightly volatile
Non Current Assets Total53.5 M45.6 M39.4 M
Slightly volatile
Non Currrent Assets Other218.9 K230.4 K651.3 K
Very volatile
Cash And Short Term Investments295.2 M390.9 M217 M
Slightly volatile
Common Stock Total Equity22.2 K33.4 K20.6 K
Slightly volatile
Common Stock Shares Outstanding21 M26.9 M32.6 M
Slightly volatile
Liabilities And Stockholders Equity354.3 M452.4 M260.6 M
Slightly volatile
Non Current Liabilities Total343.2 M326.8 M87.3 M
Slightly volatile
Other Current Assets9.5 M9.1 M3.4 M
Slightly volatile
Other Stockholder Equity738.1 M703 M268.4 M
Slightly volatile
Total Liabilities382.5 M364.3 M103.1 M
Slightly volatile
Property Plant And Equipment Gross25.7 M24.5 M6.8 M
Slightly volatile
Total Current Assets300.8 M406.8 M221.2 M
Slightly volatile
Short Term Debt2.8 M3.6 M2.2 M
Slightly volatile
Common Stock22.9 K27 K20.2 K
Slightly volatile
Other Liabilities367.6 M350.1 M102.6 M
Slightly volatile
Other Assets279.7 K294.4 K1.7 M
Pretty Stable
Long Term Debt534.4 K562.5 K3.6 M
Slightly volatile
Short and Long Term Debt1.2 M1.2 M4.3 M
Slightly volatile
Property Plant Equipment1.6 M2.4 M1.3 M
Slightly volatile
Long Term Debt Total534.4 K562.5 K3.7 M
Slightly volatile
Capital Surpluse517.6 M825.5 M345.6 M
Slightly volatile
Short Term Investments252.1 M354.9 M201.8 M
Slightly volatile
Capital Lease Obligations9.4 M17.8 M4.6 M
Slightly volatile
Net Invested Capital83.7 M88.1 M310.9 M
Slightly volatile
Long Term Investments25.7 M27 M67.7 M
Slightly volatile
Non Current Liabilities Other159 M310.8 M85.2 M
Slightly volatile
Net Working Capital425 M369.4 M320 M
Slightly volatile
Capital Stock30.2 K27 K27.4 K
Slightly volatile

AnaptysBio Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And AmortizationM2.4 M1.6 M
Slightly volatile
Interest Expense19 M18.1 M4.9 M
Slightly volatile
Selling General Administrative44 M41.9 M14.8 M
Slightly volatile
Total Revenue24.4 M17.2 M19 M
Slightly volatile
Other Operating Expenses190.6 M181.6 M69.1 M
Slightly volatile
Research Development138.9 M132.3 M53.3 M
Slightly volatile
Total Operating Expenses190.6 M181.6 M69.1 M
Slightly volatile
Cost Of Revenue2.3 M2.4 M30.4 M
Pretty Stable
Interest Income18.7 M17.8 M5.3 M
Slightly volatile
Reconciled Depreciation1.3 M2.4 M731.4 K
Slightly volatile

AnaptysBio Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation34.9 M33.2 M10.1 M
Slightly volatile
Begin Period Cash Flow131.8 M71.3 M98 M
Slightly volatile
Depreciation2.5 M2.4 M933.5 K
Slightly volatile
Other Non Cash Items7.9 M7.6 M2.9 M
Slightly volatile
Capital Expenditures572.8 K807 K427.5 K
Slightly volatile
End Period Cash Flow34.2 M36 M92.7 M
Slightly volatile
Change Receivables980 K1.1 M1.2 M
Slightly volatile
Cash Flows Other Operating31.6 M30.1 M9.4 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio31.9333.6138101
Slightly volatile
PTB Ratio6.226.54591.8 K
Slightly volatile
Days Sales Outstanding15314649.6984
Slightly volatile
Book Value Per Share3.113.27236.6019
Slightly volatile
Stock Based Compensation To Revenue2.031.93540.7484
Slightly volatile
Capex To Depreciation0.320.33960.7213
Pretty Stable
PB Ratio6.226.54591.8 K
Slightly volatile
EV To Sales30.9332.555996.0474
Slightly volatile
Days Of Inventory On Hand1.0E-41.0E-40.0
Slightly volatile
Payables Turnover0.480.505721.6321
Slightly volatile
Sales General And Administrative To Revenue2.572.44481.1501
Slightly volatile
Average Inventory0.40.450.49
Slightly volatile
Research And Ddevelopement To Revenue8.17.71014.1704
Slightly volatile
Capex To Revenue0.03540.0470.0361
Slightly volatile
Cash Per Share8.4614.51888.3316
Slightly volatile
Days Payables Outstanding758722147
Slightly volatile
Income Quality1.410.73831.2398
Slightly volatile
Current Ratio11.1710.865711.1746
Slightly volatile
Tangible Book Value Per Share3.113.27236.6019
Slightly volatile
Receivables Turnover2.382.504322.3566
Pretty Stable
Graham Number14.0721.152613.8487
Slightly volatile
Shareholders Equity Per Share3.113.27236.6019
Slightly volatile
Debt To Equity0.01920.02021.5969
Slightly volatile
Capex Per Share0.01680.030.0167
Slightly volatile
Revenue Per Share0.760.63720.7647
Slightly volatile
Interest Debt Per Share0.770.73760.3699
Slightly volatile
Debt To Assets0.00370.00390.0943
Slightly volatile
Operating Cycle15314649.6984
Slightly volatile
Price Book Value Ratio6.226.54591.8 K
Slightly volatile
Days Of Payables Outstanding758722147
Slightly volatile
Ebt Per Ebit1.170.99521.0618
Very volatile
Company Equity Multiplier4.765.13488.8891
Slightly volatile
Long Term Debt To Capitalization0.00140.00150.1746
Slightly volatile
Total Debt To Capitalization0.01880.01980.2883
Slightly volatile
Debt Equity Ratio0.01920.02021.5969
Slightly volatile
Quick Ratio11.1710.865711.1746
Slightly volatile
Net Income Per E B T1.11.01.0158
Very volatile
Cash Ratio0.910.96065.7485
Slightly volatile
Days Of Inventory Outstanding1.0E-41.0E-40.0
Slightly volatile
Days Of Sales Outstanding15314649.6984
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.811.00670.999
Slightly volatile
Price To Book Ratio6.226.54591.8 K
Slightly volatile
Fixed Asset Turnover0.890.93912.9767
Pretty Stable
Debt Ratio0.00370.00390.0943
Slightly volatile
Price Sales Ratio31.9333.6138101
Slightly volatile
Asset Turnover0.0360.03790.4829
Slightly volatile
Price Fair Value6.226.54591.8 K
Slightly volatile

AnaptysBio Fundamental Market Drivers

Cash And Short Term Investments390.9 M

AnaptysBio Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About AnaptysBio Financial Statements

AnaptysBio stakeholders use historical fundamental indicators, such as AnaptysBio's revenue or net income, to determine how well the company is positioned to perform in the future. Although AnaptysBio investors may analyze each financial statement separately, they are all interrelated. For example, changes in AnaptysBio's assets and liabilities are reflected in the revenues and expenses on AnaptysBio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in AnaptysBio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue11.7 M6.5 M
Total Revenue17.2 M24.4 M
Cost Of Revenue2.4 M2.3 M
Stock Based Compensation To Revenue 1.94  2.03 
Sales General And Administrative To Revenue 2.44  2.57 
Research And Ddevelopement To Revenue 7.71  8.10 
Capex To Revenue 0.05  0.04 
Revenue Per Share 0.64  0.76 
Ebit Per Revenue(9.58)(10.06)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether AnaptysBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AnaptysBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anaptysbio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anaptysbio Stock:
Check out the analysis of AnaptysBio Correlation against competitors.
For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AnaptysBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.05)
Revenue Per Share
2.086
Quarterly Revenue Growth
8.047
Return On Assets
(0.18)
Return On Equity
(1.62)
The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AnaptysBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if AnaptysBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AnaptysBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.